DEUTSCH / ENGLISH

PUBLICATIONS

Author, Co-Author of selected publications

• Döller G, Gröner A, Straub OC. Safety evaluation of nuclear polyhedrosis virus replication in pigs. Appl Environ Microbiol 1983;45:1229-1233 – (PDF)
  
• Gröner A, Granados RR, Burand JP. Interaction of Autography californica nuclear polyhedrosis virus with two nonpermissive cell lines. Intervirology 1984;21:203-209 – (PDF)
  
• Kuroda K, Gröner A, Frese K, Drenckhahn D, Hauser C, et al. Synthesis of biologically active influenza virus hemagglutinin in insect larvae. J Virol 1989;63:1677-1685 – (PDF)
• Grabenhorst E, Gröner A, Jäger V, Ackermann M, Karger C, et al. Comparison of the posttranslational modifications of human proteins secreted from different recombinant baculovirus infected insect cell lines. Animal Cell Technol - Products of Today, Prospects for Tomorrow. 1994;676-8. https://doi.org/10.1016/B978-0-7506-1845-8.50153-8 
• Hilfenhaus J, Gröner A, Nowak T, Weimer T. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses. Transfusion 1997;37:935-940 – (PDF)
  
• Nübling CM, Gröner A, Löwer J. GB virus C/hepatitis G virus and intravenous immunoglobulins Vox Sang 1998;75:189-192 – (PDF)
• Weimer T, Streichert S, Watson C, Gröner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001;41:1500-1504 – (PDF)
• Weimer T, Streichert S, Watson C, Gröner A. Hepatitis A virus prevalence in plasma donations. J Med Virol 2002;67:469-471 (- PDF)
  
• Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thrombosis Research 2002;105:391-400 – (PDF)
• Gröner A, Nowak T, Römisch J. Purity, activity, and virus safety of a pasteurized antithrombin concentrate. Semin Thromb Hemost 2002;28(S1):79-86  https://DOI: 10.1055/s-2002-30200 - PDF
• Vey M, Baron H, Weimer T, Gröner A. Purity of spiking agents affects partitioning of prions in plasma protein purification. Biologicals 2002;30:187-196 – (PDF)
  
• Bellon A, Seyfert-Brandt W, Lang W, Baron H, Gröner A, Vey M. Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity. J Gen Virol 2003;84:1921-1925 – (PDF)
  
• Gröner A. Qualification of virus/cell systems for their intended use. Dev Biol (Basel) 2004;118:55-63 – (PDF)
  
• Bauman PA, Lawrence LA, Biesert L, Dichtelmüller H, Fabbrizzi F, et al. Critical factors influencing prion inactivation by sodium hydroxide. Vox Sang 2006;91:34-40 – (PDF)
  
• Jones M, Peden AH, Prowse CV, Gröner A, Manson JC, et al. In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrPSc. J Pathol 2007;213:21-26 – (PDF)
  
• Stucki M, Boschetti N, Schäfer W, Hostettler T, Käsermann F, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008;36:239-247 – (PDF)
  
• Gröner A. Pathogen safety of plasma-derived products – Haemate P/Humate-P. Haemophilia 2008;14(Suppl 5);54-71 – (PDF)
  
• Dichtelmüller HO, Biesert L, Fabbrizzi F, Gajardo R, Gröner A, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009;49:1931-1943 – (PDF)
  
• Choi YP, Peden AH, Gröner A, Ironside JW, Head MW. Distinct stability states of disease-associated human prion protein identified by conformation-dependent immunoassay. J Virol 2010;84:12030-12038 – (PDF)
  
• Choi YP, Gröner A, Ironside JW, Head MW. Correlation of polydispersed prion protein and characteristic pathology in the thalamus in variant Creutzfeldt-Jakob disease: implication of small oligomeric species. Brain Pathol 2011;21:298-307 – (PDF)
  
• Choi YP, Gröner A, Ironside JW, Head MW. Comparison of the level, distribution and form of disease-associated prion protein in variant and sporadic Creutzfeldt-Jakob diseased brain using conformation-dependent immunoassay and Western blot. J Gen Virol 2011;92:727-732 – (PDF)
  
• Dichtelmüller HO, Biesert L, Fabbrizzi F, Falbo A, Flechsig E, et al. Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2011;51:1412-1430 – (PDF)
  
• Gröner A, Nowak T, Schäfer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012;52:2104-2112 – (PDF)
  
• Cai K, Gröner A, Dichtelmüller HO, Fabbrizzi F, Flechsig E, et al. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. Transfusion 2013;53:1894-1905 – (PDF)
  
• Kovacs GG, Peden A, Weis S, Höftberger R, Berghoff AS, et al. Rapidly progressive dementia with thalamic degeneration and peculiar cortical prion protein immunoreactivity, but absence of proteinase K resistant PrP: a new disease entity? Acta Neuropathol Commun 2013;1:72 – (PDF)
  
• Gröner A. Pathogen safety of Beriate. Thromb Res 2014;134(Suppl 1):S10-S15 – (PDF)
  
• Klamroth R, Gröner A, Simon TL. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates Transfusion 2014;54:1406-1417 – (PDF)
  
• Lovick S, Bycholski K, Gröner A. Defining acceptable epidemiology ranges in donor populations based on the contamination risk of finished plasma-derived products Vox Sang 2014;107:315-323 – (PDF)
  
• Solomon C, Gröner A, Ye J, Pendrak I. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data. Thromb Haemost 2015;113:759-771 – (PDF)
  
• Solomon C, Korte W, Fries D, Pendrak I, Joch C, et al. Safety of Factor XIII concentrate: analysis of more than 20 years of pharmacovigilance data. Transfus Med Hemother 2016;43:365-373 – (PDF)
  
• Kee S, Weber D, Popp B, Nowak T, Schäfer W, Gröner A, Roth NJ. Pathogen safety and characterisation of a highly purified human alpha1-proteinase inhibitor preparation. Biologicals 2017;47:25-32 – (PDF)
  
• Nowak T, Popp B, Gröner A, Schäfer W, Kalina U, et al. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration. Transfusion 2017;57:1184-1191 – (PDF)
  
• Gröner A, Broumis C, Fang R, Nowak T, Popp B, et al. Effective inactivation of a wide range of viruses by pasteurization. Transfusion 2018;58:41-51 – (PDF)
  
• Dähnert L, Eiden M, Schlosser J, Fast C, Schröder C, et al. High sensitivity of domestic pigs to intraveneous infection with HEV. BMC Vet Res 2018;14:381 – (PDF)
• Schlosser J, Dähnert L, Dremsek P, Tauscher K, Fast C, et al. Different outcomes of experimental hepatitis E virus infection in diverse mouse strains, Wistar rats, and rabbits. Viruses 2019;11:1 https://http://dx.doi.org/10.3390/v11010001 – (PDF)
• Roth NJ, Dichtelmüller HO, Fabbrizzi F, Flechsig E, Gröner A, et al. Nanofiltration as a robust method contributing to viral
  safety of plasma-derived therapeutics: 20 yearsʼ experience of the plasma protein manufacturers. Transfusion 2020;60:2661-74. https://DOI: 10.1111/trf.16022 - PDF
• Dähnert L, Schlosser J, Fast C, Fröhlich A, Gröner A, et al. Hepatitis E virus: Efficacy of pasteurization of plasma-derived VWF/FVIII concentrate determined by pig bioassay. Transfusion 2021;61:1266-77 – (PDF)
  
• Gröner A. Host range of zoonotic hepatitis E viruses. J Exp Nephrol 2021;2:15-20 – (PDF)
• Gröner A. Integration of Planova filters in manufacturing processes of biologicals improve the virus safety effectively: A review of publicly available data. Biotechnol. Prog. 2024;40:e3398. Biotechnol. Prog. 2024;40:e3398. https://doi.org/10.1002/btpr.3389 - (PDF)
• Gröner A. Virus Retentive Filters - Effective Virus Removal in the Manufacturing Process of Biologicals. Med Res Arch 2024;12(12) Online. https://doi.org/10.18103/mra.v12i12.6084  

• Gröner A, Caspari G. Pathogeneliminierung und –inaktivierung bei der Herstellung von Plasmaderivaten [Pathogen removal and inactivation during the production of plasma derivatives] in: Wallhäußers Praxis der Sterilisation, Desinfektion, Antiseptik und Konservierung,  (edit. Kramer A, Assadian O)  Georg Thieme Verlag Stuttgart – New York, 2008, pp 372-382
  
• Simon TL, Seidel K, Gröner A. Preparation of Plasma Derivatives in: Rossi’s Principles of Transfusion Medicine (edit. Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG, Petrides M) AABB Press published by Blackwell Publishing Ltd. 2009, pp 273-286
  
• Gröner A, Konrad M. Plasmafraktionierung und therapeutische Plasmaproteine [Plasma fractionation and therapeutic plasma proteins] in: Transfusionsmedizin und Immunhämatologie (edit. V. Kiefel) Springer-Verlag  2010, pp 271-286
  
• Ruiz S, Gröner A. Pharmaceuticals in: Decontamination of Prions (edit. Riesner D, Deslys J-P, Pocchiari M, Somerville R) düsseldorf university press 2012, pp 195-211
  
• Gröner A. Pathogen Safety in: Biopharmaceutical Processing (edit. Jagschies G, Lindskog E, Lacki K, Galliher P) Elsevier 2018, pp 1075-1104
• Gröner A. Assuring Pathogen Safety of the Starting Material for Plasma-Derived Products. In: Rezaei, Nima, Encyclopedia of Infection and Immunity. 2022; vol. 4, pp. 430-449. Oxford: Elsevier. dx.doi.org/10.1016/B978-0-12-818731-9.00147-6